HutchMed CEO On Novel Drug Pricing Strategy In China
Prospects After New Approval, HK Listing
A successful IPO on the Hong Kong Stock Exchange will jump-start the company’s R&D and new drug approvals, says HutchMed's CEO in an interview.
You may also be interested in...
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Cost concerns and an increased number of potential entrants will dominate the annual adjustments to China's the national reimbursement drug list, with regulators moving to manage companies' expectations.
Private Company Edition: Sirnaomics planned to go public after its series D, but its new venture capital does not prevent it from doing so in the near term. Also, Vida Ventures and Novalis Biotech raised new VC funds to back start-ups and ArriVent launched with up to $150m in series A cash.